Skip to main content
SpringerLink
Log in

PET and PET/CT Imaging in Colorectal Cancer

  • Chapter
Positron Emission Tomography

  • 2318 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clinicians 1999;49(1):8–31.

    CAS  Google Scholar 

  2. Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer (Phila) 1998;82(6):1197–1207.

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8–29.

    Article  PubMed  Google Scholar 

  4. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27(2):94–106.

    Article  PubMed  CAS  Google Scholar 

  5. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000;97(16):9226–9233.

    Article  PubMed  CAS  Google Scholar 

  6. Schiepers C, Hoh CK. Positron emission tomography as a diagnostic tool in oncology. Eur Radiol 1998;8(8):1481–1494.

    Article  PubMed  CAS  Google Scholar 

  7. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83(12):1607–1611.

    Article  PubMed  CAS  Google Scholar 

  8. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Costeffectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23(6):737–743.

    Article  PubMed  CAS  Google Scholar 

  9. Arulampalam TH, Costa DC, Loizidou M, Visvikis D, Ell PJ, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg 2001;88(2):176–189.

    Article  PubMed  CAS  Google Scholar 

  10. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999;26(5):577–583.

    PubMed  CAS  Google Scholar 

  11. Anderson H, Price P. What does positron emission tomography offer oncology? Eur J Cancer 2000;36(16):2028–2035.

    Article  PubMed  CAS  Google Scholar 

  12. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231(2):305–332.

    PubMed  Google Scholar 

  13. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001;11(10):1968–1974.

    Article  PubMed  CAS  Google Scholar 

  14. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (St. Louis) 1986;100(2):278–284.

    PubMed  CAS  Google Scholar 

  15. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270(8):943–947.

    Article  PubMed  CAS  Google Scholar 

  16. Charnley RM. Imaging of colorectal carcinoma. Radiology 1990;174(1):283–283.

    PubMed  CAS  Google Scholar 

  17. Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver. Gastrointestinal-Tumor-Study-Group Protocol-6584. J Clin Oncol 1991;9(7):1105–1112.

    PubMed  Google Scholar 

  18. McDaniel KP, Charnsangavej C, Dubrow RA, Varma DGK, Granfield CAJ, Curley SA. Pathways of nodal metastasis in carcinomas of the cecum, ascending colon, and transverse colon: CT demonstration. Am J Roentgenol 1993;161(1):61–64.

    CAS  Google Scholar 

  19. Nelson RC, Chezmar JL, Sugarbaker PH, Bernardino ME. Hepatic tumors: comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989;172(1):27–34.

    PubMed  CAS  Google Scholar 

  20. Coleman RE. FDG imaging. Nucl Med Biol 2000;27(7):689–690.

    Article  PubMed  CAS  Google Scholar 

  21. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, et al. Whole-body positron emission tomography. 1. Methods and performance characteristics. J Nucl Med 1992;33(6):1191–1199.

    PubMed  CAS  Google Scholar 

  22. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996;17(3):197–198.

    PubMed  CAS  Google Scholar 

  23. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206(3):755–760.

    PubMed  CAS  Google Scholar 

  24. Falk PM, Gupta NC, Thorson AG, Frick MP, Boman BM, Christensen MA, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994;37(2):153–156.

    Article  PubMed  CAS  Google Scholar 

  25. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40(10):1195–1204.

    Article  PubMed  CAS  Google Scholar 

  26. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989;170(2):329–332.

    PubMed  CAS  Google Scholar 

  27. Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182(2):549–552.

    PubMed  CAS  Google Scholar 

  28. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41(7):1177–1189.

    PubMed  CAS  Google Scholar 

  29. Warburg O. On the origin of cancer cells. Science 1956;123:309–314.

    Article  PubMed  CAS  Google Scholar 

  30. Wahl RL. Targeting glucose transporters for tumor imaging: sweet idea, sour result. J Nucl Med 1996;37(6):1038–1041.

    PubMed  CAS  Google Scholar 

  31. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23(10):1409–1415.

    Article  PubMed  CAS  Google Scholar 

  32. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images [see comments]. Eur J Nucl Med 1997;24(9):1091–1098.

    PubMed  CAS  Google Scholar 

  33. Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999;26(1):31–38.

    Article  PubMed  CAS  Google Scholar 

  34. Wahl RL. To AC or not to AC: that is the question. J Nucl Med 1999;40(12):2025–2028.

    PubMed  CAS  Google Scholar 

  35. Metser U. 18F-FDG PET in evaluating patients treated for metastatic colorectal cancer: can we predict prognosis? J Nucl Med 2004;45(9):1428–1430.

    PubMed  Google Scholar 

  36. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999;86(7):932–937.

    Article  PubMed  CAS  Google Scholar 

  37. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35(1):164–167.

    PubMed  CAS  Google Scholar 

  38. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-L8]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189(3):847–850.

    PubMed  CAS  Google Scholar 

  39. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;27(7):647–655.

    Article  PubMed  CAS  Google Scholar 

  40. Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von Schulthess GK. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 2002;29(7):922–927.

    Article  PubMed  CAS  Google Scholar 

  41. Goerres GW, Hany TF, Kamel E, von Schulthess GK, Buck A. Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants. Eur J Nucl Med Mol Imaging 2002; 29(3):367–370.

    Article  PubMed  CAS  Google Scholar 

  42. Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, et al. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med 2004;45(2):290–293.

    PubMed  Google Scholar 

  43. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 2004;45(5):797–801.

    PubMed  Google Scholar 

  44. Beets G, Penninckx F, Schiepers C, Filez L, Mortelmans L, Kerremans R, et al. Clinical value of whole-body positron emission tomography with [F-18]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81(11):1666–1670.

    PubMed  CAS  Google Scholar 

  45. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171(1):21–26.

    Article  PubMed  CAS  Google Scholar 

  46. Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131(7):703–707.

    PubMed  CAS  Google Scholar 

  47. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography [see comments]. Ann Surg Oncol 1997;4(8):613–620.

    Article  PubMed  CAS  Google Scholar 

  48. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21(5):517–522.

    Article  PubMed  CAS  Google Scholar 

  49. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, Jr., et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38(8):1196–1201.

    PubMed  CAS  Google Scholar 

  50. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17(3):894–901.

    PubMed  CAS  Google Scholar 

  51. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134(5):503–511; discussion 511–513.

    Article  PubMed  CAS  Google Scholar 

  52. Schiepers C, Hoh CK. Clinical positron imaging in oncology. In: Schiepers C, editor. Diagnostic Nuclear Medicine, 1st ed. Berlin: Springer-Verlag, 2000:159–176.

    Google Scholar 

  53. Delbeke D, Valk PE. Positron tomography imaging: diagnosis and management of colorectal carcinoma. In: Khalkhali IMJ, Goldsmith SJ, editors. Nuclear Oncology: Diagnosis and Therapy: Lippincott, Williams & Wilkins, 2001:351–360.

    Google Scholar 

  54. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22(3):332–337.

    Article  PubMed  CAS  Google Scholar 

  55. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rect 2000;43(6):759–767; discussion 767–770.

    Article  CAS  Google Scholar 

  56. Fong YM, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of F-18-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178(4):282–287.

    Article  PubMed  CAS  Google Scholar 

  57. Topal B, Flamen P, Aerts R, D’Hoore A, Filez L, Van Cutsem E, et al. Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001;27(2):175–179.

    Article  PubMed  CAS  Google Scholar 

  58. Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am Surg 1999;65(12):1183–1185.

    PubMed  CAS  Google Scholar 

  59. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240(3):438–447; discussion 447–450.

    PubMed  Google Scholar 

  60. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16(3):1075–1084.

    PubMed  CAS  Google Scholar 

  61. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer [see comments]. Ann Surg 1998;227(3):319–323.

    Article  PubMed  CAS  Google Scholar 

  62. Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, et al. 16. FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 patients. Clin Positron Imaging 2000;3(4):170.

    Article  PubMed  Google Scholar 

  63. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37(7):862–869.

    Article  PubMed  CAS  Google Scholar 

  64. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233(3):293–299.

    Article  PubMed  CAS  Google Scholar 

  65. Staib L, Schirrmeister H, Reske SN, Beger HG. Is F-18-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180(1):1–5.

    Article  PubMed  CAS  Google Scholar 

  66. Imdahl A, Reinhardt MJ, Nitzsche EU, Mix M, Dingeldey A, Einert A, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385(2):129–134.

    Article  PubMed  CAS  Google Scholar 

  67. Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, et al. Impact of F-18-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med 2001;42(4):586–590.

    PubMed  CAS  Google Scholar 

  68. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43(4):492–499.

    PubMed  Google Scholar 

  69. Desai DC, Zervos EE, Arnold MW, Burak WE Jr, Mantil J, Martin EW Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003;10(1):59–64.

    Article  PubMed  Google Scholar 

  70. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32(4):623–648.

    PubMed  CAS  Google Scholar 

  71. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Irngartinger G, Oberdorfer F, et al. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1998;39(3):465–473.

    PubMed  CAS  Google Scholar 

  72. Mantaka P, Strauss AD, Strauss LG, Moehler M, Goldschmidt H, Oberdorfer F, et al. Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET). Anticancer Res 1999;19(5C):4443–4450.

    PubMed  CAS  Google Scholar 

  73. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer (Phila) 1998;83(2):245–253.

    Article  PubMed  CAS  Google Scholar 

  74. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mähler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998;39(7):1197–1202.

    PubMed  CAS  Google Scholar 

  75. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J Clin Oncol 1996;14(3):700–708.

    PubMed  CAS  Google Scholar 

  76. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer (Phila) 1996;78(10):2216–2222.

    Article  PubMed  CAS  Google Scholar 

  77. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32(8):1485–1490.

    PubMed  CAS  Google Scholar 

  78. Abe Y, Matsuzawa T, Fujiwara T, Fukuda H, Itoh M, Yamada K, et al. Assessment of radiotherapeutic effects on experimental tumors using fluorine-18 2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 1986;12(7):325–328.

    Article  PubMed  CAS  Google Scholar 

  79. Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer (Phila) 1999;85(4):803–811.

    Article  PubMed  CAS  Google Scholar 

  80. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [F-18]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35(13):1773–1782.

    Article  PubMed  CAS  Google Scholar 

  81. Gambhir SS, Valk P, Shepherd J, Hoh C, Allen M, Phelps ME. Costeffective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer. J Nucl Med 1997;38(suppl):90P–91P.

    Google Scholar 

  82. Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001; 233(3):310–319.

    Article  PubMed  CAS  Google Scholar 

  83. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41(8):1369–1379.

    PubMed  CAS  Google Scholar 

  84. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348(25):2500–2507.

    Article  PubMed  Google Scholar 

  85. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of FDG-PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797–1803.

    PubMed  Google Scholar 

  86. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999;40(4):591–603.

    PubMed  CAS  Google Scholar 

  87. Schiepers C, Yap C S, Quon A, Giuliano P, Silverman DH, Dahlbom M, et al. Added value of PET/CT for cancer staging and lesion localization. Eur J Nucl Med Mol Imaging 2003;30(8):S227–S228.

    Google Scholar 

  88. Goerres GW, Burger C, Schwitter MW, Heidelberg TN, Seifert B, Von Schulthess GW. PET/CT of the abdomen: optimizing the patient breathing pattern. Eur Radiol 2003;13(4):734–739.

    PubMed  Google Scholar 

  89. Dizendorf E, Hany TF, Buck A, Von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003;44(5):732–738.

    PubMed  Google Scholar 

  90. Cohade C, Osman M, Nakamoto Y, Marshall LT, Links JM, Fishman EK, et al. Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 2003;44(3):412–416.

    PubMed  Google Scholar 

  91. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat (“USA-Fat”: description on 18F-FDG PET/CT. J Nucl Med 2003;44(2):170–176.

    PubMed  CAS  Google Scholar 

  92. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57(3):853–863.

    Article  PubMed  Google Scholar 

  93. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004;45(suppl 1):82S–95S.

    PubMed  Google Scholar 

  94. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41(4):661–681.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Christiaan Schiepers MD, PhD

  2. Northern California PET Imaging Center, Sacramento, CA, USA

    Peter E. Valk MB, BS, FRACP

Authors
  1. Christiaan Schiepers MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter E. Valk MB, BS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California PET Imaging Center, Sacramento, CA, USA

    Peter E. Valk MB, BS, FRACP

  2. Positron Emission Tomography, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

    Dominique Delbeke MD, PhD (Professor and Director of Nuclear Medicine) (Professor and Director of Nuclear Medicine)

  3. Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

    Dale L. Bailey PhD (Associate Professor of Medicine) (Associate Professor of Medicine)

  4. Cancer Imaging and Tracer Development Program, The University of Tennessee Medical Center, Knoxville, TN, USA

    David W. Townsend PhD (Director) (Director)

  5. Department of Radiological Sciences, Guy’s and St Thomas’ Clinical PET Centre, Guy’s and St Thomas’ Hospital Trust, London, UK

    Michael N. Maisey BSc, MD, FRCR, FRCP (Professor of Emeritus) (Professor of Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Schiepers, C., Valk, P.E. (2006). PET and PET/CT Imaging in Colorectal Cancer. In: Valk, P.E., Delbeke, D., Bailey, D.L., Townsend, D.W., Maisey, M.N. (eds) Positron Emission Tomography. Springer, London . https://doi.org/10.1007/1-84628-187-3_10

Download citation

  • DOI: https://doi.org/10.1007/1-84628-187-3_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-971-5

  • Online ISBN: 978-1-84628-187-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation